Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Amgen agrees to buy Dutch firm Dezima Pharma in $1.55bn deal
Amgen agrees to buy Dutch firm Dezima Pharma in $1.55bn deal
Amgen has entered a definitive acquisition agreement with Dutch biotechnology firm Dezima Pharma for $1.
Purdue University-Based Pharmaceutical Startup To Participate In American Chemical Society
Purdue University-Based Pharmaceutical Startup To Participate In American Chemical Society
WEST LAFAYETTE, Ind.
Allergan and Gedeon Richter Plc. Receive FDA Approval of VRAYLAR™ (cariprazine) for Treatment of Manic or Mixed Episodes of Bipolar I Disorder and Schizophrenia in Adults
Allergan and Gedeon Richter Plc. Receive FDA Approval of VRAYLAR™ (cariprazine) for Treatment of Manic or Mixed Episodes of Bipolar I Disorder and Schizophrenia in Adults
DUBLIN and BUDAPEST, Hungary, Sept.
FDA asks Pfizer for Zoloft label update highlighting birth defect risks
FDA asks Pfizer for Zoloft label update highlighting birth defect risks
For years, Pfizer ($PFE) has shrugged off claims that its antidepressant Zoloft causes heart defects in newborns, fighting a raft of litigation alleging that the company did not adequately war...
Ventrix Initiates Clinical Trial of VentriGel
Ventrix Initiates Clinical Trial of VentriGel
SAN DIEGO, CA, USA September 17, 2015.
Invokana diabetes drug faces Canadian class-action lawsuit
Invokana diabetes drug faces Canadian class-action lawsuit
The diabetes drug Invokana, recently adopted by Nova Scotia's pharmacare program, is now the subject of a national class-action lawsuit.
Amgen bets up to $1.7B on Xencor's antibody technology
Amgen bets up to $1.7B on Xencor's antibody technology
Amgen ($AMGN) is teaming up with Xencor ($XNCR) through a heavily back-loaded deal worth as much as $1.
Nurix, Celgene partner to develop new therapies for oncology immunology and immuno-oncology
Nurix, Celgene partner to develop new therapies for oncology immunology and immuno-oncology
Nurix and Celgene have partnered to develop and commercialize novel small molecule therapeutics in the fields of oncology, inflammation, immunology and immuno-oncology.
FDA Warnings Target Drug Companies in New Zealand, India
FDA Warnings Target Drug Companies in New Zealand, India
Sept.
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma
PRINCETON, N.
Obama nominates Robert Califf as FDA commissioner
Obama nominates Robert Califf as FDA commissioner
President Barack Obama has nominated Dr.
Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal
Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal
Competition is heating up in the GLP-1 diabetes market, and Novo Nordisk ($NVO) is doing what it can to line up data behind its long-dominant drug, Victoza.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand